Generic HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE INN entry, drug patent expiry and freedom to operate

Sponsor	Phase
VA Office of Research and Development
US Department of Veterans Affairs

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solvay	RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	088376-001	Oct 28, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chartwell Rx	CAM-AP-ES	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	084897-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Solvay	SER-A-GEN	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	087210-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sun Pharm Industries	RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	088570-001	Apr 10, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	085549-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	085771-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lederle	RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	087709-001	May 13, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 15, 2026

What are the current market positions of these drugs?

Hydralazine hydrochloride, hydrochlorothiazide, and reserpine serve specific roles in hypertension and heart failure management. Hydrochlorothiazide, a thiazide diuretic, holds a dominant share in hypertension treatment with global sales exceeding $2 billion annually as of 2022 (Statista). Hydralazine hydrochloride and reserpine have smaller markets, primarily due to their age, side effect profiles, and decreased use in favor of newer agents.

Market Sizes (2022 Estimates):

Drug	Estimated Global Sales	Key Markets	Main Indication
Hydrochlorothiazide	>$2 billion	US, Europe, Asia	Hypertension, edema
Hydralazine hydrochloride	~$300 million	US, Europe	Hypertensive emergencies, heart failure
Reserpine	<$50 million	Limited; FDA-approved use cases	Hypertension, psychiatric conditions

What are the drivers influencing demand?

Hydrochlorothiazide remains a first-line agent for hypertension, included in most combination pills. Its affordability underpins continued demand, especially in cost-sensitive markets like India and Southeast Asia.
Hydralazine hydrochloride is prescribed mainly for acute hypertensive crises and heart failure, especially in populations with limited access to newer agents.
Reserpine has diminished in use due to psychiatric side effects and availability of safer alternatives but persists in certain regions with legacy prescribing practices.

What factors hinder market growth?

Patent expirations for hydrocholorothiazide and hydralazine have led to the widespread availability of generics, suppressing prices and margins.
The advent of angiotensin receptor blockers (ARBs), ACE inhibitors, and calcium channel blockers reduces reliance on older agents like reserpine and hydralazine.
Side effect profiles (e.g., reserpine-associated depression and sedation) limit use in favor of newer drugs with better safety profiles.

How does the patent landscape affect financial prospects?

Hydrochlorothiazide patents expired in the mid-2000s, leading to extensive generics. The low-cost competition constrains profit margins but sustains volume.
Hydralazine hydrochloride formulations are largely off-patent; however, some branded versions remain in specific markets, influencing pricing.
Reserpine patents expired in the 1970s; its use is now mainly off-patent and limited to legacy markets, with little room for premium pricing.

What are the key regulatory and policy influences?

Drugs like hydrochlorothiazide face scrutiny due to potential risks of non-melanoma skin cancer, leading to safety warnings that can impact prescribing trends (FDA, 2018).
Governments and health agencies promote the use of cost-effective medications, favoring generic prescriptions, which diminishes revenues for branded formulations.
New regulations in emerging markets may demand bioequivalence data, complicating manufacturing but not significantly affecting established generics.

What is the outlook for revenue trajectories?

Hydrochlorothiazide sales are projected to decline marginally due to market saturation and safety concerns, but volumes remain stable thanks to low cost.
Hydralazine hydrochloride sales could stabilize or slightly increase in markets where it is used for acute hypertensive episodes, especially if new formulations or delivery methods are introduced.
Reserpine sales are expected to remain minimal, limited to select legacy markets or niche indications.

Projected Revenue Windows (2023-2028):

Drug	CAGR (Compound Annual Growth Rate)	Notes
Hydrochlorothiazide	-1% to 0%	Market saturation; generic competition
Hydralazine hydrochloride	1% to 3%	Possible niche growth; demand in emergencies
Reserpine	0%	Lack of growth; market decline phased out

What strategic considerations should stakeholders analyze?

Focus on formulations with improved safety or delivery, such as sustained-release hydroxyzine or patch formulations, may reclaim some market share.
Opportunities exist in markets with less access to newer medications (e.g., parts of Africa, Southeast Asia), where affordability is paramount.
Expansion into combination therapies incorporating these drugs could sustain revenues; e.g., hydrochlorothiazide with other antihypertensives.
R&D efforts might target repositioning or development of analogs with improved safety profiles.

Key Takeaways

Hydrochlorothiazide leads in revenue volume owing to its affordability and widespread use for hypertension.
Hydralazine hydrochloride remains niche but can see localized demand for emergency and heart failure indications.
Reserpine's market is shrinking; off-patent status and safety concerns limit its future prospects.
Patent expirations and safety considerations depress potential margins; generic competition dominates.
Emerging markets retain demand mostly driven by cost factors, offering opportunities for low-cost generics.

FAQs

1. Will the market for hydrochlorothiazide decline significantly in the next five years?
The overall decline is slow and likely limited to a few percentage points annually due to global reliance on this medication for hypertension management, especially in low-income regions.

2. Are there opportunities to reformulate hydralazine or reserpine for better safety or efficacy?
Yes. Developing sustained-release formulations or combination medications could improve safety profiles and enhance therapeutic adherence.

3. How do patent expirations influence market competition for these drugs?
Patent expirations in the mid-2000s for hydrochlorothiazide led to an influx of generics, drastically reducing prices and margins. Similar expirations for hydralazine and reserpine have resulted in minimal branded sales.

4. What are the regulatory risks affecting these medications globally?
Safety concerns, especially with hydrochlorothiazide's potential links to skin cancer, have led to regulatory advisories, influencing prescribing practices and demand.

5. Is there a growth opportunity in combination therapies involving these drugs?
Yes. Generic companies can develop fixed-dose combinations to improve compliance, potentially capturing market share in hypertension therapy segments.

References

[1] Statista. (2022). Global hypertension drug sales.
[2] FDA. (2018). Safety Announcement on Hydrochlorothiazide.
[3] MarketWatch. (2023). Analysis of legacy antihypertensive markets.

US Patents:	0
Tradenames:	12
Applicants:	9
NDAs:	16
Clinical Trials:	1
DailyMed Link:	hydralazine hydrochloride; hydrochlorothiazide; reserpine at DailyMed

Hydralazine hydrochloride; hydrochlorothiazide; reserpine - Generic Drug Details

What are the generic drug sources for hydralazine hydrochloride; hydrochlorothiazide; reserpine and what is the scope of freedom to operate?

Summary for hydralazine hydrochloride; hydrochlorothiazide; reserpine

Recent Clinical Trials for hydralazine hydrochloride; hydrochlorothiazide; reserpine

Anatomical Therapeutic Chemical (ATC) Classes for hydralazine hydrochloride; hydrochlorothiazide; reserpine

US Patents and Regulatory Information for hydralazine hydrochloride; hydrochlorothiazide; reserpine

Market Dynamics and Financial Trajectory for Hydralazine Hydrochloride, Hydrochlorothiazide, and Reserpine